Stromal Reprogramming Optimizes KRAS-Specific Chemotherapy Inducing Antitumor Immunity in Pancreatic Cancer
ACS Applied Materials & Interfaces · 2024
DOI: 10.1021/acsami.4c10404 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2024. Verfasst von Qinglian Hu und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou 310032, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Tumor Microenvironment, Deoxycytidine. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou 310032, China.
ORCID-Profile: Qinglian Hu, Yuanxiang Jin
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Hu, Q., Feng, J., Qi, L., & Jin, Y. (2024). Stromal Reprogramming Optimizes KRAS-Specific Chemotherapy Inducing Antitumor Immunity in Pancreatic Cancer. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.4c10404
Vancouver
Hu Q, Feng J, Qi L, Jin Y. Stromal Reprogramming Optimizes KRAS-Specific Chemotherapy Inducing Antitumor Immunity in Pancreatic Cancer. ACS Applied Materials & Interfaces. 2024. doi:10.1021/acsami.4c10404
BibTeX
@article{Hu2024,
author = {Hu, Qinglian and Feng, Jiayu and Qi, Lulu and Jin, Yuanxiang},
title = {Stromal Reprogramming Optimizes KRAS-Specific Chemotherapy Inducing Antitumor Immunity in Pancreatic Cancer},
journal = {ACS Applied Materials & Interfaces},
year = {2024},
doi = {10.1021/acsami.4c10404}
}
EUVIMED